Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?

Overview

Provided by

This educational activity is supported by educational grants from Sanofi and Karyopharm Therapeutics.

Release date: 02/10/2023
Expiration date: 02/10/2024
Estimated time to complete: 0.25-hours
Activity URL: https://cme.healio.com/hematology-oncology/ace-the-case/20230206/3-multiple-myeloma

Activity Description

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.

This educational program is designed to meet the educational needs of the members of the care team (oncologists, hematologists, nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals) who manage patients with relapsed/refractory multiple myeloma.

Faculty Educators

Nisha Joseph, MD
Assistant Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Winship Summer Scholars Program
Winship Cancer Institute of Emory University

Kathryn Maples, PharmD, BCOP
Multiple Myeloma Clinical Pharmacy Specialist
Adjunct Faculty, Mercer University
PGY2 Oncology Research Coordinator
Emory University

Patricia Mangan, MSN, CRNP
Nurse Practitioner, Medicine (Hematology/Oncology)
Perelman School of Medicine
University of Pennsylvania

Learning Objectives

After participating in the activity, learners should be better able to:

• Consider the role of newly approved agents and emerging strategies in treating newly diagnosed and RRMM based upon information in clinical guidelines and expert insights
• Outline interprofessional approaches to manage patients with RRMM and recognize and mitigate toxicities associated with newly approved agents
• Describe patient and caregiver education for newly approved agents, including early recognition of toxicities and communication with health care team to mitigate the risk of developing severe complications

Accreditation and Credit Designation

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Pharmacists

This activity provides 0.25 ACPE contact hours (0.025 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-23-005-H01-P. Knowledge

Nurse Practitioners and Nurses

American Academy of CME, Inc., designates this enduring educational activity for 0.25 ANCC contact hours (0.25 pharmacotherapeutic contact hours).

Other members of the care team will receive a certificate of participation.

Disclosures

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educators

Nisha Joseph, MD
No relevant financial relationships with ineligible companies to disclose.

Kathryn Maples, PharmD, BCOP
Dr. Maples discloses the following relevant relationships with ineligible companies:
Advisory Board/Consultant: Janssen*, Karyopharm*, Sanofi*, GlaxoSmithKline*, Pfizer 

Patricia Mangan, MSN, CRNP
Ms. Mangan discloses the following relevant relationships with ineligible companies:
Speakers Bureau: Bristol Myers Squibb, Amgen, Janssen, Takeda, Karyopharm, GlaxoSmithKline

Independent Clinical Reviewer

Val Adams, PharmD
Advisory Board/Consultant: Bristol Myers Squibb*
Grant/Research Support: Bristol Myers Squibb*

*financial relationship has ended

Planning Committee

John JD Juchniewicz, MCIS, CHCP, FACEHP, Wendy Gloffke, PhD, Natalie Kirkwood RN, BSN, JD, and Paul J. Miniter, MS, American Academy of CME: No relevant financial relationships with ineligible companies to disclose.

This activity includes the mention of investigational drugs and/or off-label usage.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE/CPE/CE credit and for physicians to be eligible to earn ABIM MOC points for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.

For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique ABIM ID when completing the activity evaluation. Physicians who do not know their ABIM ID can log in to the ABIM website at https://www.abim.org — your ABIM ID will appear next to your name.

By claiming MOC points, you are agreeing to have your participation completion information to be shared with the ACCME and the ABIM. Your points will be automatically submitted to the ABIM on your behalf; please allow 6-8 weeks for your points to display on the ABIM website.

Hardware/Software Requirements

Please ensure the computer you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2023. This accredited continuing education activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).